Mga Batayang Estadistika
| LEI | 549300O8WKLP8QEG5U47 |
| CIK | 771856 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Champions Oncology, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy State |
|
| August 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| July 23, 2025 |
EXHIBIT 19 Champions Oncology, Inc. Insider Trading Policy Adopted December 15, 2018 This Insider Trading Policy (the “Policy”) of Champions Oncology, Inc. (together with its subsidiaries, the “Company”) prohibits the unauthorized disclosure and misuse of any non-public information you obtain in the course of your service with the Company and the misuse of material non-public information in securi |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 23, 2025 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| July 23, 2025 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Champions Oncology Reports Record Annual Revenue of $57 Million Total annual revenue growth of 14% Hackensack, NJ – July 23, 2025 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading translational oncology research organization, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2025. F |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2025 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY |
|
| July 21, 2025 |
Exhibit 99.1 One University Plaza, Suite 307 Hackensack, NJ 07601 Champions Oncology Announces Appointment of New CEO Hackensack, NJ – July 18, 2025 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading provider of oncology-focused CRO services specializing in preclinical and clinical specialty testing, today announced that its Board of Directors has appointed Rob Brainin as Chief Executive Officer |
|
| July 21, 2025 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (“Agreement”) between Champions Oncology, Inc. (the “Company”), a Delaware corporation, and Robert Brainin (the “Executive”), dated this 16th day of July 2025, effective as of the 16th day of July 2025 (the “Effective Date”). W I T N E S S E T H WHEREAS, the Company desires to employ the Executive and to enter into an agreement to reflect |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 21, 2025 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| March 17, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, IN |
|
| March 11, 2025 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Record Quarterly Revenue of $17.0 Million Record Net Income of $4.5 Million Hackensack, NJ – March 11, 2025 – Champions Oncology, Inc. (Nasdaq: CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial |
|
| March 11, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 11, 2025 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| March 3, 2025 |
Champions Oncology, Inc. One University Plaza Suite 307 Hackensack, New Jersey 07601 Champions Oncology, Inc. One University Plaza Suite 307 Hackensack, New Jersey 07601 VIA EDGAR March 3, 2025 U.S. Securities & Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Bonnie Baynes and Angela Connell Re: Champions Oncology, Inc. Form 10-K for the Fiscal Year Ended April 30, 2024 Form 8-K dated December 11, 2024 File |
|
| February 14, 2025 |
Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Schedule 13G Amendment No. |
|
| December 16, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, IN |
|
| December 11, 2024 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 million Hackensack, NJ – December 11, 2024 – Champions Oncology, Inc. (Nasdaq: CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial resul |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 11, 2024 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) ( |
|
| November 14, 2024 |
CSBR / Champions Oncology, Inc. / West Elk Partners, LP Passive Investment SC 13G/A 1 fp0091019-1sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2) Champions Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 15870P307 (CUSIP Number) Septembe |
|
| October 30, 2024 |
Filing Fee Table (Filed herewith) Exhibit 107 Calculation of Filing Fee Table Form S-8 Champions Oncology, Inc. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule Amount registered (1)(2) Proposed maximum offering price per share Maximum aggregate offering price (3) Fee Rate Amount of registration fee (3)(4) Equity Common Stock, $0.001 par value - 2021 Equity Incentive Pl |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Champions Oncology, Inc. (Exact name of registrant as specified in charter) Delaware 52-140175 (State or Other Jurisdiction of Incorporation or Organization) (IRS Employer Identification No.) One University Plaza, Suite 307 Hackensack, New Jersey 07601 (Address o |
|
| October 15, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 14, 2024 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (I |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 3, 2024 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IR |
|
| September 13, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. |
|
| September 11, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 11, 2024 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) |
|
| September 11, 2024 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million Hackensack, NJ – September 11, 2024 – Champions Oncology, Inc. (Nasdaq: CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial resu |
|
| August 27, 2024 |
DEFA14A 1 noticeandaccesscardfy24pro.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permit |
|
| August 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy State |
|
| July 19, 2024 |
Description of Registered Securities Exhibit 4.1 RIDER X DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of the April 30, 2024, Champions Oncology, Inc. has authorized capital stock consisting of 200,000,000 shares of common stock, par value $0.001 per share. The following description summarizes the material terms of common stock. Holders of our common |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2024 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY |
|
| July 19, 2024 |
Policy Related to Recovery of Erroneously Awarded Compensation, adopted December 1, 2023* EXHIBIT 97 Clawback Policy CHAMPIONS ONCOLOGY, INC. EXECUTIVE COMPENSATION CLAWBACK POLICY Adopted as of December 1, 2023 The Board of Directors (the “Board”) of Champions Oncology, Inc. (the “Company”) has adopted the following executive compensation clawback policy (this “Policy”). This Policy shall supplement any other clawback or compensation recovery policy or policies adopted by the Company |
|
| July 19, 2024 |
Exhibit 21 SUBSIDIARIES OF CHAMPIONS ONCOLOGY, INC. Name Incorporated in Champions Oncology UK Limited United Kingdom Champions Oncology, Israel, Limited Israel Champions Oncology, SRL Italy Corellia AI Inc United States |
|
| July 18, 2024 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Champions Oncology Reports Quarterly Revenue of $14.0 Million Annual Revenue of $50.2 Million Hackensack, NJ – July 18, 2024 – Champions Oncology, Inc. (Nasdaq: CSBR), a leader in the development of advanced preclinical oncology solutions, today announced its financial results for the fiscal year and fourth quarter ended April |
|
| July 18, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 18, 2024 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| May 6, 2024 |
SC 13D/A 1 nea14-champions18831.htm NEW ENTERPRISE ASSOCIATES 14, L.P. - CHAMPIONS ONCOLOGY 13D/A(#1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Champions Oncology, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 15870P307 (CUSIP Number) Stephanie Brecher New E |
|
| March 15, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, IN |
|
| March 12, 2024 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Quarterly Revenue of $12.0 Million Hackensack, NJ – March 12, 2024 – Champions Oncology, Inc. (Nasdaq: CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its third quarter of fiscal |
|
| March 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 12, 2024 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| February 12, 2024 |
CSBR / Champions Oncology, Inc. / TOCQUEVILLE ASSET MANAGEMENT L.P. Passive Investment SC 13G 1 d1097264313-g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Champions Oncology, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 15870P307 (CUSIP Number) December 28, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| December 13, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, IN |
|
| December 12, 2023 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Quarterly Revenue of $11.6 Million Hackensack, NJ – December 12, 2023 – Champions Oncology, Inc. (Nasdaq: CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fis |
|
| December 12, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 12, 2023 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) ( |
|
| October 19, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 19, 2023 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (I |
|
| October 17, 2023 |
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Announces the Addition of Brady Davis as President HACKENSACK, NJ – OCTOBER 17th, 2023, 8:30AM - Champions Oncology, Inc. (Nasdaq: CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions has appointed Brady Davis as President to continue |
|
| October 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 9, 2023 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IR |
|
| September 13, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. |
|
| September 13, 2023 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Quarterly Revenue of $12.6 Million Hackensack, NJ – September 13, 2023 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its fin |
|
| September 13, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 13, 2023 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) |
|
| August 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| August 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy State |
|
| July 24, 2023 |
Description of Registered Securities Exhibit 4.1 RIDER X DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of the April 30, 2023, Champions Oncology, Inc. has authorized capital stock consisting of 200,000,000 shares of common stock, par value $0.001 per share. The following description summarizes the material terms of common stock. Holders of our common |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 24, 2023 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| July 24, 2023 |
Exhibit 21 SUBSIDIARIES OF CHAMPIONS ONCOLOGY, INC. Name Incorporated in Champions Oncology UK Limited United Kingdom Champions Oncology, Israel, Limited Israel Champions Oncology, SRL Italy |
|
| July 24, 2023 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Champions Oncology Reports Quarterly Revenue of $13.1 Million Record Annual Revenue of $53.9 Million Hackensack, NJ – July 24, 2023 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today a |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY |
|
| April 5, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 5, 2023 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Inc |
|
| April 5, 2023 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Announces $5M Stock Repurchase Program Hackensack, NJ – April 5, 2023, Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced that its Board of Directo |
|
| March 16, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, IN |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 15, 2023 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| March 15, 2023 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Quarterly Revenue of $12.8 Million Hackensack, NJ – March 15, 2023 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financi |
|
| December 13, 2022 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Record Quarterly Revenue of $14.3 Million Hackensack, NJ ? December 13, 2022 ? Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced i |
|
| December 13, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, IN |
|
| December 13, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 13, 2022 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) ( |
|
| October 20, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 20, 2022 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (I |
|
| September 12, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. |
|
| September 8, 2022 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Record Quarterly Revenue of $13.7 Million Hackensack, NJ ? September 8, 2022 ? Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced i |
|
| September 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 8, 2022 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) ( |
|
| August 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy State |
|
| August 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| August 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| July 22, 2022 |
Description of Registered Securities Exhibit 4.1 RIDER X DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of the April 30, 2022, Champions Oncology, Inc. has authorized capital stock consisting of 200,000,000 shares of common stock, par value $0.001 per share. The following description summarizes the material terms of common stock. Holders of our common |
|
| July 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY |
|
| July 21, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 21, 2022 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| July 21, 2022 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Champions Oncology Reports Quarterly Revenue of $12.9 Million Record Annual Revenue of $49.1 Million Hackensack, NJ ? July 21, 2022 ? Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today a |
|
| March 15, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, IN |
|
| March 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 15, 2022 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| March 15, 2022 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Record Quarterly Revenue of $13.2 Million Reported Adjusted EBITDA of $1.5 million Hackensack, NJ ? March 15, 2022 ? Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-mu |
|
| February 14, 2022 |
CSBR / Champions Oncology Inc / West Elk Partners, LP Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) Champions Oncology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 15870P307 (CUSIP Number) December 31, 2021 (Date of Event Which Re |
|
| December 13, 2021 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Record Quarterly Revenue of $11.8 Million Reported income from operations of $263,000 Hackensack, NJ ? December 13, 2021 ? Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative pharmacology, biomark |
|
| December 13, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, IN |
|
| December 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 13, 2021 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) ( |
|
| October 21, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 20, 2021 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (I |
|
| September 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 13, 2021 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) |
|
| September 13, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. |
|
| September 13, 2021 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Record Quarterly Revenue of $11.3 Million Hackensack, NJ ? September 13, 2021 ? Champions Oncology, Inc. (Nasdaq: CSBR), leaders in transformative technology solutions utilized in drug discovery and development, today announced its financial results for its first quarter of fiscal 20 |
|
| September 13, 2021 |
Section 302 Certification of Principal Financial Officer EXHIBIT 31.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER I, David Miller, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Champions Oncology, Inc., a Delaware corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under w |
|
| September 13, 2021 |
EXHIBIT 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE U.S. SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Champions Oncology, Inc. (the “Company”) on Form 10-Q for the period ended July 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities |
|
| September 13, 2021 |
Section 302 Certification of Principal Executive Officer EXHIBIT 31.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER I, Ronnie Morris, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Champions Oncology, Inc., a Delaware corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under |
|
| September 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| August 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| July 26, 2021 |
Description of Registered Securities Exhibit 4.1 RIDER X DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of the April 30, 2021, Champions Oncology, Inc. has authorized capital stock consisting of 200,000,000 shares of common stock, par value $0.001 per share. The following description summarizes the material terms of common stock. Holders of our common |
|
| July 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY |
|
| July 23, 2021 |
EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock of Champions Oncology, Inc. |
|
| July 23, 2021 |
CSBR / Champions Oncology Inc / West Elk Partners, LP Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) Champions Oncology Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 15870P307 (CUSIP Number) July 13, 2021 (Date of Event Which Requires Filing of This Sta |
|
| July 22, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 22, 2021 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| July 22, 2021 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Champions Oncology Reports Quarterly Revenue of $10.6 Million Record Annual Revenue of $41 Million Hackensack, NJ ? July 22, 2021 ? Champions Oncology, Inc. (Nasdaq: CSBR), engaged in creating transformative technology solutions to be utilized in drug discovery and development, today announced its financial results for the year |
|
| March 15, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, IN |
|
| March 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 31, 2021 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (I |
|
| March 11, 2021 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Record Quarterly Revenue of $10.8 Million Hackensack, NJ – March 11, 2021 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery and development through data-driven research strategies and innovative p |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 12, 2021 (February 8, 2021) CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commis |
|
| December 14, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, IN |
|
| December 14, 2020 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Record Quarterly Revenue of $10.1 Million Launches Lumin Bioinformatics SaaS platform Hackensack, NJ – December 14, 2020 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery through innovative pharma |
|
| December 14, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 31, 2020 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (I |
|
| October 21, 2020 |
Submission of Matters to a Vote of Security Holders - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 21, 2020 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (I |
|
| October 15, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 15, 2020 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (I |
|
| October 15, 2020 |
irdeckfinal15oct2020 Creating Greater Certainty in the Fight Against Cancer ACCELERATING DRUG DISCOVERY Investor Relations Presentation October 2020 Notice of Forward-Looking Statements This presentation contains certain “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources. |
|
| September 14, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2020 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. |
|
| September 14, 2020 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Record Quarterly Revenue of $9.5 Million Hackensack, NJ – September 14, 2020 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced i |
|
| September 14, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 14, 2020 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) |
|
| September 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defi |
|
| September 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| August 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin |
|
| July 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2020 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY |
|
| July 28, 2020 |
Description of Registered Securities * Exhibit 4.1 RIDER X DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of the April 30, 2020, Champions Oncology, Inc. has authorized capital stock consisting of 200,000,000 shares of common stock, par value $0.001 per share. The following description summarizes the material terms of common stock. Holders of our common |
|
| July 27, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 27, 2020 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| July 27, 2020 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Quarterly Revenue of $8.8 Million Record Annual Revenue of $32.1 Million Hackensack, NJ – July 27, 2020 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncolo |
|
| March 30, 2020 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 26, 2020 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| March 16, 2020 |
CSBR / Champions Oncology, Inc. 10-Q - Quarterly Report - 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2020 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, IN |
|
| March 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 12, 2020 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| March 12, 2020 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Record Quarterly Revenue of $9.0 Million Hackensack, NJ – March 12, 2020 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its f |
|
| January 3, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 3, 2020 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IR |
|
| January 3, 2020 |
championsoncologyinvesto INVESTOR RELATIONS PRESENTATION – DECEMBER 2019 NOTICE OF FORWARD-LOOKING STATEMENTS This presentation contains certain “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources. |
|
| December 16, 2019 |
CSBR / Champions Oncology, Inc. 10-Q - Quarterly Report - 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2019 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, IN |
|
| December 16, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 16, 2019 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) ( |
|
| December 16, 2019 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Quarterly Revenue of $7.6 Million Records Second Quarter Income of $291,000 Hackensack, NJ – December 16, 2019 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of |
|
| October 16, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 16, 2019 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (I |
|
| September 16, 2019 |
CSBR / Champions Oncology, Inc. 10-Q - Quarterly Report - 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2019 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. |
|
| September 16, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 16, 2019 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) |
|
| September 16, 2019 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Quarterly Revenue of $6.7 Million Hackensack, NJ – September 16, 2019 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its fina |
|
| September 5, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 5, 2019 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) ( |
|
| September 5, 2019 |
irpresentationjuly2019 Investor Presentation July 2019 Confidential 1 Notice of Forward Looking Statements This presentation contains certain “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources. |
|
| August 28, 2019 |
CSBR / Champions Oncology, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin |
|
| July 29, 2019 |
CSBR / Champions Oncology, Inc. 10-K - Annual Report - 10-K 10-K 1 csbr10-k4302019.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file num |
|
| July 15, 2019 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Record Quarterly Revenue of $7.7 Million For The Fourth Quarter Ended April 30, 2019 Record Annual Revenue of $27 Million Hackensack, NJ – July 15, 2019 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize |
|
| July 15, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 15, 2019 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| March 18, 2019 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Quarterly Revenue of $6.4 Million Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019 Hackensack, NJ – March 18, 2019 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to |
|
| March 18, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 18, 2019 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| March 18, 2019 |
CSBR / Champions Oncology, Inc. 10-Q (Quarterly Report) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2019 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, IN |
|
| January 7, 2019 |
irpresentation1718 Investor Presentation January 2019 Confidential 1 Notice of Forward Looking Statements This presentation contains certain “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources. |
|
| January 7, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 7, 2019 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 (State or Other Jurisdiction (Commission File Number) of Incorporati |
|
| December 17, 2018 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Record Quarterly Revenue of $6.7 Million Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019 Hackensack, NJ – December 17, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and s |
|
| December 17, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 17, 2018 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) ( |
|
| December 17, 2018 |
CSBR / Champions Oncology, Inc. 10-Q (Quarterly Report) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2018 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, IN |
|
| October 16, 2018 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 16, 2018 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (I |
|
| September 14, 2018 |
CSBR / Champions Oncology, Inc. 10-Q (Quarterly Report) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2018 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. |
|
| September 13, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 13, 2018 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) |
|
| September 13, 2018 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Record Quarterly Revenue of $6.2 Million Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019 Hackensack, NJ – September 13, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and |
|
| August 28, 2018 |
CSBR / Champions Oncology, Inc. DEF 14A DEF 14A 1 schedule14aproxy2018.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only |
|
| August 7, 2018 |
CSBR / Champions Oncology, Inc. / Fields ephraim - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Champions Oncology, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 15870P307 (CUSIP Number) Ephraim Fields c/o Echo Lake Capital 888 Seventh Avenue, 17th Floor New York, NY 10019 (Name, Address and Telephone Number of |
|
| July 30, 2018 |
CSBR / Champions Oncology, Inc. 10-K (Annual Report) 10-K 1 csbr10-k4302018.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file num |
|
| July 26, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 26, 2018 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| July 26, 2018 |
EX-99.1 2 csbr8-k4302018exhibit991.htm EXHIBIT 99.1 Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Record Annual Revenue Exceeding $20M for Fiscal Year Ended April 30, 2018 Expects Revenue Growth of at Least 20% for Fiscal Year 2019 Hackensack, NJ – July 26, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the developme |
|
| March 19, 2018 |
CSBR / Champions Oncology, Inc. 10-Q (Quarterly Report) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2018 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, IN |
|
| March 15, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 15, 2018 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| March 15, 2018 |
EX-99.1 2 csbr8-k1312018exhibit991.htm EXHIBIT 99.1 Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Quarterly Revenue of $5.1 Million Company Generates Positive Cash Flow from Operations; Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2018 Hackensack, NJ – March 15, 2018 – Champions Oncology, Inc. (Nasd |
|
| March 12, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 12, 2018 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| March 12, 2018 |
EX-99.1 2 csbrirpresentationdec201.htm EXHIBIT 99.1 1 Investor Presentation December 2017 NASDAQ: CSBR 2 Notice of Forward Looking Statements This presentation contains certain “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources. These forward-lo |
|
| December 15, 2017 |
CSBR / Champions Oncology, Inc. 10-Q (Quarterly Report) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2017 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, IN |
|
| December 7, 2017 |
CSBR / Champions Oncology, Inc. 8-K (Current Report) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 7, 2017 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File N |
|
| December 7, 2017 |
Exhibit Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Record Quarterly Revenue of $5.2 Million Quarterly operating profit driven by double-digit revenue growth Hackensack, NJ ? December 7, 2017 ? Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the d |
|
| October 16, 2017 |
Submission of Matters to a Vote of Security Holders Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 16, 2017 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File N |
|
| October 4, 2017 |
Champions Oncology 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 4, 2017 (September 29, 2017) CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdictio |
|
| September 14, 2017 |
Exhibit Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Record Quarterly Revenue of $5 Million 37.1% year-over-year revenue increase Hackensack, NJ ? September 14, 2017 ? Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncol |
|
| September 14, 2017 |
Champions Oncology 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 14, 2017 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File |
|
| September 14, 2017 |
CSBR / Champions Oncology, Inc. 10-Q (Quarterly Report) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2017 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. |
|
| August 31, 2017 |
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| August 28, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin |
|
| August 8, 2017 |
CSBR / Champions Oncology, Inc. / PESSIN NORMAN H - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Champions Oncology, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 15870P307 Cusip Number Norman H. Pessin Brian Pessin 366 Madison Avenue, 14th Floor New York, NY 10017 212-661-2670 (Name, Address and Telephone Numb |
|
| July 28, 2017 |
Exhibit 21 SUBSIDIARIES OF CHAMPIONS ONCOLOGY, INC. Name Incorporated in Champions Biotechnology U.K., Limited United Kingdom Champions Oncology (Israel) Ltd. Israel |
|
| July 28, 2017 |
CSBR / Champions Oncology, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2017 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY |
|
| July 27, 2017 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports 38% Revenue Growth for Fiscal Year Ended April 30, 2017 Hackensack, NJ – July 27, 2017 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its fin |
|
| July 27, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 csbr8-k4302017.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 27, 2017 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction ( |
|
| May 9, 2017 |
8-K 1 form8-kamendedbylawx2017.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 9, 2017 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisd |
|
| May 9, 2017 |
CHAMPIONS ONCOLOGY, INC. AMENDED AND RESTATED BY-LAWS Dated May 9, 2017 ARTICLE I Stockholders Exhibit Exhibit 3.1 CHAMPIONS ONCOLOGY, INC. AMENDED AND RESTATED BY-LAWS Dated May 9, 2017 ARTICLE I Stockholders Section 1.1 Annual Meetings. The annual meeting of the stockholders of the Company for the election of Directors and for the transaction of such other business as properly may come before such meeting shall be held at such place either within or outside the State of Delaware at such d |
|
| April 28, 2017 |
Champions Oncology 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 28, 2017 (April 24, 2017) CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Co |
|
| March 17, 2017 |
Champions Oncology 10-Q (Quarterly Report) Document SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2017 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONC |
|
| March 16, 2017 |
Champions Oncology 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 16, 2017 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Num |
|
| March 16, 2017 |
Exhibit Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports 40% Revenue Growth Hackensack, NJ – March 16, 2017 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the third |
|
| January 26, 2017 |
Champions Oncology 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 26, 2017 (November 29, 2016) CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdictio |
|
| January 13, 2017 |
SC 13D 1 formsc13d.htm NORMAN H. PESSIN SC 13D 1-12-2017 (CHAMPIONS ONCOLOGY, INC) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Champions Oncology, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 15870P307 Cusip Number Norman H. Pessin Brian Pessin 366 Madison Ave |
|
| December 14, 2016 |
Champions Oncology 10-Q (Quarterly Report) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2016 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, IN |
|
| December 13, 2016 |
CSBR / Champions Oncology, Inc. / Fields ephraim - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Champions Oncology, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 15870P307 (CUSIP Number) Ephraim Fields c/o Echo Lake Capital 888 Seventh Avenue, 17th Floor New York, NY 10019 (Name, Address and Telephone Number of |
|
| November 29, 2016 |
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Exhibit Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports 50% Revenue Growth, Accelerated Progress on Path to Profitability and Future Role Changes of the Senior Leadership Hackensack, NJ ? November 29, 2016 ? Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to persona |
|
| November 29, 2016 |
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 29, 2016 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File |
|
| November 1, 2016 |
8-K 1 csbr8-k10252016.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 28, 2016 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdicti |
|
| October 28, 2016 |
CSBR / Champions Oncology, Inc. / PAR INVESTMENT PARTNERS LP - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Champions Oncology, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 15870P307 (CUSIP Number) c/o PAR Investment Partners, L.P. One International Place, Suite 2401 Boston, MA 02110 Attn: Steven M. Smith (617) |
|
| October 14, 2016 |
Submission of Matters to a Vote of Security Holders Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 13, 2016 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File N |
|
| September 14, 2016 |
Champions Oncology 10-Q (Quarterly Report) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2016 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, INC. |
|
| September 9, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 9, 2016 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) ( |
|
| September 9, 2016 |
EX-99.1 2 csbr8-k7312016exhibit991.htm EXHIBIT 99.1 Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Beats Revenue Guidance for Quarter; Reaffirms Full Year Guidance of 43 - 60% Revenue Growth Hackensack, NJ – September 9, 2016 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and servic |
|
| August 25, 2016 |
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| August 25, 2016 |
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| July 29, 2016 |
Champions Oncology 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2016 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY |
|
| July 29, 2016 |
EX-21 2 csbrex21.htm EXHIBIT 21 Exhibit 21 SUBSIDIARIES OF CHAMPIONS ONCOLOGY, INC. Name Incorporated in Champions Biotechnology U.K., Limited United Kingdom Champions Oncology (Israel) Ltd. Israel Champions Oncology Singapore Pte Ltd. Singapore |
|
| July 28, 2016 |
Exhibit Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Announces Revenue Up 26%, Projects 43% - 60% Growth For Current Fiscal Year Hackensack, NJ ? July 28, 2016 ? Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, tod |
|
| July 28, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 28, 2016 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Numb |
|
| July 22, 2016 |
Exhibit OPTION EXCHANGE AGREEMENT This Option Exchange Agreement (this ? Agreement ?) is dated as of July 19, 2016 between Champions Oncology, Inc. |
|
| July 22, 2016 |
Champions Oncology 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 19, 2016 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11540 52-1401755 (State or Other Jurisdiction (Commission File Numb |
|
| July 22, 2016 |
Exhibit OPTION EXCHANGE AGREEMENT This Option Exchange Agreement (this ? Agreement ?) is dated as of July 19, 2016 between Champions Oncology, Inc. |
|
| July 22, 2016 |
Exhibit OPTION EXCHANGE AGREEMENT This Option Exchange Agreement (this ? Agreement ?) is dated as of July 19, 2016 between Champions Oncology, Inc. |
|
| June 15, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 v4423528k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 15, 2016 (June 9, 2016) CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other |
|
| June 15, 2016 |
Exhibit 99.1 Contacts: Champions Oncology, Inc. Susan Foreman [email protected] Telephone: 410-369-0365 Champions Oncology, Inc. Announces Pricing of Public Offering of Common Stock 2,000,000 Shares Priced at $2.25 Per Share Hackensack, N.J., June 9, 2016 ? Champions Oncology, Inc. (NASDAQ: CSBR), or the ?Company?, a company engaged in the development and sale of advanced technology s |
|
| June 15, 2016 |
CHAMPIONS ONCOLOGY, INC. 2,000,000 SHARES OF COMMON STOCK UNDERWRITING AGREEMENT Exhibit 1.1 CHAMPIONS ONCOLOGY, INC. 2,000,000 SHARES OF COMMON STOCK UNDERWRITING AGREEMENT June 9, 2016 National Securities Corporation 410 Park Avenue 14th Floor New York, NY 10022 Ladies and Gentlemen: Champions Oncology, Inc., a Delaware corporation (the ?Company?) proposes, subject to the terms and conditions stated herein, to issue and sell to National Securities Corporation and each of the |
|
| June 15, 2016 |
Champions Oncology, Inc. Announces Closing of Public Offering of Common Stock Exhibit 99.2 Contacts: Champions Oncology, Inc. Susan Foreman [email protected] Telephone: 410-369-0365 Champions Oncology, Inc. Announces Closing of Public Offering of Common Stock Hackensack, N.J., June 15, 2016 ? Champions Oncology, Inc. (NASDAQ: CSBR), or the ?Company?, a company engaged in the development and sale of advanced technology solutions and products to personalize the d |
|
| June 10, 2016 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-210924 PROSPECTUS Champions Oncology, Inc. 2,000,000 shares of Common Stock We are offering 2,000,000 shares of our common stock, par value $0.001 per share, in a firm commitment underwritten offering. The public offering price is $2.25 per share. Our common stock is currently traded on the Nasdaq Capital Market under the symbol CSBR. On June |
|
| June 8, 2016 |
Champions Oncology, Inc. One University Plaza, Suite 307 Hackensack, New Jersey 07601 June 8, 2016 VIA EDGAR Scot Foley United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Champions Oncology, Inc. Registration Statement on Form S-1 Filed April 26, 2016, as amended File No. 333-210924 Dear Mr. Foley: Pursuant to Rule 461 und |
|
| June 8, 2016 |
ESTABLISHED 1947 Member FINRA/SIPC June 8, 2016 Via EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street, N. |
|
| May 24, 2016 |
CHAMPIONS ONCOLOGY, INC. _____________ SHARES OF COMMON STOCK UNDERWRITING AGREEMENT Exhibit 1.1 CHAMPIONS ONCOLOGY, INC. SHARES OF COMMON STOCK UNDERWRITING AGREEMENT May , 2016 National Securities Corporation 410 Park Avenue 14th Floor New York, NY 10022 Ladies and Gentlemen: Champions Oncology, Inc., a Delaware corporation (the ?Company?) proposes, subject to the terms and conditions stated herein, to issue and sell to National Securities Corporation and each of the other Under |
|
| May 24, 2016 |
S-1/A 1 v440247s1a.htm S-1/A As filed with the Securities and Exchange Commission on May 24, 2016 Registration No. 333-210924 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CHAMPIONS ONCOLOGY, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 2836 52-1401755 (State or oth |
|
| May 23, 2016 |
Champions Oncology, Inc. One University Plaza, Suite 307 Hackensack, New Jersey 07601 VIA EDGAR May 23, 2016 US Securities and Exchange Commission Division of Investment Management 100 F Street, N.E. Washington, DC 20549 Attn: Mary Beth Breslin RE: Champions Oncology, Inc. Registration Statement on Form S-1 Filed April 26, 2016 File No. 333-210924 Dear Ms. Breslin: On behalf of Champions Oncology, |
|
| May 18, 2016 |
Champions Oncology FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 18, 2016 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS E |
|
| May 18, 2016 |
1 Investor Presentation May 2016 Exhibit 99.1 1 Investor Presentation May 2016 2 Notice of Forward Looking Statements Thispresentationcontainscertain?forward-lookingstatements,?whichincludeinformationrelatingtofutureevents, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources. These forward-looking statements include, without limitation, statements regarding pr |
|
| April 26, 2016 |
S-1 1 v437292s1.htm S-1 As filed with the Securities and Exchange Commission on April 26, 2016 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CHAMPIONS ONCOLOGY, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 2836 52-1401755 (State or other jurisdiction of incorpora |
|
| April 13, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 13, 2016 (April 11, 2016) CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction of Incorpora |
|
| April 13, 2016 |
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 For Immediate Release Champions Oncology Announces Addition to Board of Directors HACKENSACK, N.J., April 12, 2016 - Champions Oncology, Inc. (NASDAQ:CSBR) is pleased to announce the appointment of Dr. Philip Breitfeld to its Board of Directors. Dr. Breitfeld has more than 30 years of experience in oncology. H |
|
| March 25, 2016 |
Champions Oncology FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 25, 2016 (March 21, 2016) CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction of Incorpora |
|
| March 16, 2016 |
Champions Oncology FORM 10-Q (Quarterly Report) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2016 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, IN |
|
| March 15, 2016 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Results for the Third Quarter Ended January 31, 2016 Hackensack, NJ ? March 15, 2016 ? Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial res |
|
| March 15, 2016 |
Champions Oncology 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 15, 2016 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| March 7, 2016 |
1 Investor Presentation March 2016 Exhibit 99.1 1 Investor Presentation March 2016 2 Notice of Forward Looking Statements This presentation contains certain ?forward - looking statements,? which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources . These forward - looking statements include, without limitation, stat |
|
| March 7, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 7, 2016 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| December 15, 2015 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2015 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-11504 CHAMPIONS ONCOLOGY, IN |
|
| December 14, 2015 |
Champions Oncology Reports Results for the Second Quarter Ended October 31, 2015 Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Results for the Second Quarter Ended October 31, 2015 Hackensack, NJ – December 14, 2015 – Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial |
|
| December 14, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 14, 2015 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) ( |
|
| October 29, 2015 |
Champions Oncology FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 26, 2015 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 0-17263 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| October 15, 2015 |
424B3 1 v422204424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-204050 PROSPECTUS Champions Oncology, Inc. 2,939,252 shares of Common Stock 1,616,594 shares of Common Stock issuable upon the exercise of Warrants This prospectus relates to the resale by certain selling security holders of Champions Oncology, Inc. of up to 4,555,846 shares of our common stock in connection with |
|
| October 15, 2015 |
Submission of Matters to a Vote of Security Holders 8-K 1 v4220958k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 13, 2015 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 0-17263 52-1401755 (State or Other Jurisdiction |
|
| September 25, 2015 |
As filed with the Securities and Exchange Commission on September 25, 2015 Registration No. |
|
| September 11, 2015 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2015 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17263 CHAMPIONS ONCOLOGY, INC. (E |
|
| September 10, 2015 |
Champions Oncology 8-K CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 10, 2015 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 0-17263 52-1401755 (State or Other Jurisdiction (Commission File Number) (I |
|
| September 10, 2015 |
Champions Oncology Reports Results for the First Quarter Ended July 31, 2015 EX-99.1 2 v419946ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Results for the First Quarter Ended July 31, 2015 Hackensack, NJ – September 10, 2015 – Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncolog |
|
| September 1, 2015 |
Champions Oncology FORM DEFR14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defi |
|
| August 31, 2015 |
Champions Oncology FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| August 31, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 28, 2015 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 0-17263 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| August 28, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| August 21, 2015 |
Champions Oncology 8-K CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 21, 2015 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 0-17263 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| August 21, 2015 |
Champions Oncology Announces Uplisting to NASDAQ EX-99.1 2 v418844ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 One University Plaza Suite 307 Hackensack, NJ 07601 Phone: 201-808-8400 www.championsoncology.com Champions Oncology Announces Uplisting to NASDAQ Hackensack, NJ – August 21, 2015 – Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, |
|
| August 20, 2015 |
Champions Oncology FORM 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(B) OR (G) OF THE SECURITIES EXCHANGE ACT OF 1934 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as defined in its charter) Delaware 52-1401755 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) |
|
| August 13, 2015 |
Exhibit 3(i) |
|
| August 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 11, 2015 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 0-17263 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS |
|
| August 13, 2015 |
Champions Oncology Announces Reverse Stock Split in Preparation for Uplisting to NASDAQ Exhibit 99.1 Champions Oncology Announces Reverse Stock Split in Preparation for Uplisting to NASDAQ Hackensack, NJ ? August 12, 2015 ? Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced a 1-for-12 reverse stock split of the Company?s authorized, issued and outstand |
|
| July 29, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2015 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-17263 CHAMPIONS ONCOLOGY, |
|
| July 28, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 28, 2015 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 0-17263 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Em |
|
| July 28, 2015 |
Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400 Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 Hackensack, NJ ? July 28, 2015 ? Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financi |
|
| July 23, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 2, 2015 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 0-17263 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Emp |
|
| May 19, 2015 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-204050 PROSPECTUS Champions Oncology, Inc. 35,271,052 shares of Common Stock 19,399,078 shares of Common Stock issuable upon the exercise of Warrants This prospectus relates to the resale by certain selling security holders of Champions Oncology, Inc. of up to 54,670,130 shares of our common stock in connection with the resale of: · up to 35,27 |
|
| May 11, 2015 |
As filed with the Securities and Exchange Commission on May 11, 2015 S-1 1 v409686s1.htm S-1 As filed with the Securities and Exchange Commission on May 11, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CHAMPIONS ONCOLOGY, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or organizati |
|
| May 11, 2015 |
TO PURCHASE COMMON STOCK CHAMPIONS ONCOLOGY, INC. EXHIBIT 10.11 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR ANY STATE SECURITIES LAW, AND MAY NOT BE OFFERED FOR SALE, SOLD OR TRANSFERRED UNLESS A REGISTRATION STATEMENT UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS SHALL BE EFFECTIVE WITH RESPECT THERETO, OR AN EXEMPTIO |
|
| April 28, 2015 |
Champions Oncology FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 24, 2015 CHAMPIONS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 0-17263 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS E |
|
| April 28, 2015 |
Exhibit 3(i) CERTIFICATE OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION OF CHAMPIONS ONCOLOGY, INC. |
|
| March 30, 2015 |
Champions Oncology FORM DEF 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c-101) INFORMATION REQUIRED IN INFORMATION STATEMENT SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x D |
